Interestingly, Garfield et al. advised caution regarding the routine administration of thyroid hormone replacement, noting it could potentially promote tumor growth in patients with active cancers, particularly given evidence suggesting that hypothyroidism might have a protective effect in these patients [38]. While Garfield et al. recommend against routine hormone replacement therapy in CML patients [38], this approach may not be universally applicable, as the decision remains context-dependent and is still debated within the field. The gene discussed is TG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.